















1566Revascularization of occluded renal artery stent grafts after
complex endovascular aortic repair and its impact on renal
function
Nikolaos Konstantinou, MD,a Tilo Kölbel, MD, PhD,b Nuno V. Dias, MD, PhD,c Eric Verhoeven, MD, PhD,d
Anders Wanhainen, MD, PhD,e Mauro Gargiulo, MD, PhD,f Kyriakos Oikonomou, MD, PhD,g
Fabio Verzini, MD, PhD,h Franziska Heidemann, MD,b Bjorn Sonesson, MD, PhD,c
Athanasios Katsargyris, MD, PhD,d Kevin Mani, MD, PhD,e Carlota F. Prendes, MD,a,e Enrico Gallitto, MD, PhD,f
Karin Pfister, MD, PhD,g Maria Antonella Ruffino, MD, PhD,h Emanuel R. Tenorio, MD, PhD,i
Francesco Speziale, MD, PhD,j Stephan Haulon, MD, PhD,k Gustavo S. Oderich, MD, PhD,i and
Nikolaos Tsilimparis, MD, PhD,a Munich, Hamburg, Nuremberg, and Regensburg, Germany; Malmö and Uppsala,
Sweden; Bologna, Turin, and Rome, Italy; Rochester, Minn; and Paris, FranceABSTRACT
Background: Acute occlusion of renal bridging stent grafts after fenestrated/branched endovascular aortic repair (F/B-
EVAR) is an acknowledged complication with high morbidity that often results in chronic dialysis dependence. The feasi-
bility and effect of timely or late ($6 hours of ischemia) renal artery revascularization has not been adequately reported.
Methods: We performed a retrospective, multicenter study across 11 tertiary institutions of all consecutive patients who
had undergone revascularization of renal artery stent graft occlusions after complex EVAR. The end points were technical
success, association between ischemia time and renal function salvage, interventional complications, mortality, andmid-
term outcomes.
Results: From 2009 to 2019, 38 patients with 46 target vessels (TVs; eight bilateral occlusions) were treated for renal artery
occlusions after complex EVAR (mean age, 63.5 6 10 years; 63.2% male). Six patients had a solitary kidney (15.8%). Of the
38 patients, 16 (42.1%) had undergone FEVAR and 22 (57.9%) had undergone BEVAR. The technical success rate was
95.7% (44 of 46 TVs). The recanalization technique used was sole aspiration thrombectomy in 5.3%, aspiration throm-
bectomy and stent graft relining in 52.6%, and sole stent graft relining in 36.8%. The median renal ischemia time was
27.5 hours (range, 4-720 hours; interquartile range, 4-36 hours). Most patients (94.4%) had been treated after $6 hours of
renal ischemia time, and 55.6% had been treated after 24 hours. In 14 patients (36.8%), renal function had improved after
intervention (mean glomerular filtration rate improvement, 14.2 6 9 mL/min/1.73 m2). However, 24 patients (63.2%)
showed no improvement. Improvement of renal function did not correlate with the length of renal ischemia time. Of the
14 patients with bilateral renal artery occlusion or a solitary kidney, 9 experienced partial recovery of renal function and no
longer required hemodialysis. In-hospital mortality was 2.6%. The cause of renal stent graft occlusion could not be
identified in 50% of the TVs (23 of 46). However, in 19 (41.3%), significant stenosis or a kink of the renal stent graft was
found. The median follow-up was 11 months (interquartile range, 0-28 months). The estimated 1-year patient survival and
patency rate of the renal stent grafts was 97.4% and 83.8%, respectively.
Conclusions: Revascularization of occluded renal bridging stent grafts after F/B-EVAR is a safe and feasible technique
and can lead to significant improvement of renal function, even after long ischemia times (>24 hours) of the renal pa-
renchyma or bilateral occlusion, as long as residual perfusion of the renal parenchyma has been preserved. Also, the long-
term patency rates justify aggressive management of renal artery occlusion after F/B-EVAR. (J Vasc Surg 2021;73:1566-72.)
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ARTICLE HIGHLIGHTS
d Type of Research: An international, multicenter,
retrospective, cohort study
d Key Findings: A total of 38 patients with occlusion of
the renal artery stent graft after complex endovascu-
lar aortic repair underwent endovascular recanaliza-
tion after a median of 27.5 hours of renal ischemia
time. The technical success rate was 95.7%. Of 14 pa-
tients with bilateral occlusions or a solitary kidney, 9
no longer required hemodialysis, despite the pro-
longed ischemia time.
d Take Home Message: Revascularization of occluded
renal bridging stent grafts after fenestrated/
branched endovascular aortic repair can lead to sig-
nificant improvement of renal function even after
long ischemia times of >24 hours.dition that can cause significantmorbidity, including diffi-
cult to control hypertension and a decrease in renal
functionor can lead tohemodialysis in thecaseof bilateral
occlusion or occlusion of a solitary kidney artery. Clinical
presentation can vary among patients, most of whom
will presentwithflankpain in thefirsthours after theevent.
However, patients canalsopresentwith fever, nausea and/
or vomiting, or diarrhea.1,2 The varied clinical presentation,
combinedwith the low clinical suspicion owing to the rar-
ity of the condition, can lead to a significant delay in treat-
ment, which can, in turn, negatively affect the outcome.
Theocclusionof the renal arterieshasbecomemore rele-
vant than ever in the era of complex endovascular aortic
surgery, with the calculated risk of occlusion of the renal
bridging stent grafts reaching as high as 9% in the first
4 years after fenestrated and/or branched (F/B)-endovas-
cular aortic repair (EVAR).3 Althoughmedical and surgical
treatment of symptomatic chronic renal artery stenosis or
occlusion has been adequately studied, to the best of our
knowledge, no therapeutic protocol or optimal periodhas
been established for the revascularization of acute RAO.
Since the first successful intervention of an acute renal ar-
teryembolism in 1937,4 only case reports andsmall case se-
ries have been reported. These reports have shown that
even late revascularization of acute RAOs can lead to
symptom improvement and salvage of the function of
previously normal renal parenchyma,5,6 in contrast to the
previously commonly accepted dogma that kidney
ischemia >6 hours will lead to irreversible damage.
In the present multicenter study, we recruited cases of
acute renal stent graft occlusion after complex EVAR
from experienced centers to study the feasibility of revas-
cularization and its effects on renal function.METHODS
We performed a multicenter, retrospective study of the
data collected in the RENUVAR (renal function salvage af-
ter fenestrated and branched EVAR) registry. The study
complied with the Declaration of Helsinki, with the data
collectionandanalysisapprovedbythe localethiccommit-
tee. The institutional reviewboardwaived the requirement
for written patient consent for the present retrospective
study. A total of 11 medical centers participated in the pre-
sent study, 10 European and one North American
(Table I). The participating centers were chosen because
of their high volume of complex aortic repair and previous
participation inmulticenter complex aortic studies. All pa-
tient data, including demographics, intraoperative and
postoperative values, and outcome data, were collected
from the individual institutes separately using a standard-
ized datasheet with clearly predefined variables.
Indications and patient selection. Patients with com-
plex aortic pathologies that had been treated with F/B-
EVAR and had experienced occlusion of one or bothrenal bridging stent grafts were included in the present
study. Patients with isolated, spontaneous renal artery
occlusion without previous EVAR and patients who had
been conservatively treated for the stent graft occlusion
were excluded. Patients treated with chimney/snorkel
EVAR were also excluded. The renal stent graft occlusion,
defined as the total loss of bridging stent or stent graft
lumen patency, was confirmed using either computed
tomography angiography (CTA) or duplex ultrasonogra-
phy. Although the precise decision and indication of the
treatment algorithm differed slightly among the
participating centers, revascularization of the occluded
renal bridging stent grafts was attempted when the
renal parenchyma showed remaining perfusion in the
late/venous phase of the CTA or on the ultrasound scan,
regardless of the ischemia time.
Definitions. Occlusion was defined as the total loss of
lumen patency of the bridging stent graft after com-
plex EVAR, with or without a reduction in kidney func-
tion. Complex EVAR was defined as the endovascular
treatment of aortic pathologies with F/B-EVAR extending
to or above the level of the renal arteries, including the
pararenal, suprarenal, thoracoabdominal, and post-
dissection aortic aneurysms. Technical success was
defined as successful endovascular recanalization of the
renal stent graft without remaining high-grade stenosis
(>70%) or a type III endoleak on the final angiogram.
Successful recanalization with minimal or no flow to the
renal parenchyma on the final angiogram was still
considered technical success as long as the relevant hi-
lum branches of the renal artery had been preserved.
Clinical success was defined as termination of hemodi-
alysis therapy or improvement in renal function in pa-
tients who had not previously required hemodialysis. As
a measure of clinical success, we defined the change in
glomerular filtration rate (DGFR) as the difference
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May 2021between the last known GFR after renal recanalization
and the GFR before renal artery occlusion (DGFR equal
to GFR postoperatively minus GFR before the occlusion
event). The estimated time of renal ischemia was calcu-
lated as the interval between the appearance of the first
symptoms or the first detection of elevated serum creat-
inine levels in the blood sample and renal stent graft
intervention.
End point definitions. The primary end points of the
present study were the technical success of the revascu-
larization as defined and the degree of renal function
improvement or deterioration after intervention and dur-
ing the course of follow-up. Mortality and morbidity
(including major stroke and vascular complications)
during the early postoperative period (first 30 days) and
during follow-up and the investigation and determina-
tion of causal factors for renal endograft occlusion were
defined as the secondary end points of the present study.
Measurements of renal function and degree of func-
tion impairment. Impairment in renal function is re-
ported in terms of acute kidney injury (AKI) for all
patients in the present cohort and was classified accord-
ing to the 2012 clinical practice guidelines proposed by
the Kidney Disease Improving Global Outcomes
(KDIGO).7 Using the KDIGO criteria, AKI was defined as
an increase in serum creatinine by $0.3 mg/dL within
48 hours or an increase in serum creatinine to $1.5 times
the baseline value within the previous 7 days. Stage 1 AKI
corresponds to an increase in serum creatinine to 1.5 to1.9 times the baseline value, stage 2 as 2 to 2.9 times the
baseline values, and stage 3 as an increase in serum
creatinine to three times the baseline value, a serum
creatinine value of >4 mg/dL, or the initiation of renal
replacement therapy (hemodialysis).
Several patients had presented with chronic kidney dis-
ease (CKD) before the renal artery occlusion event. CKD
was defined as either kidney damage or a decreased
GFR of <90 mL/min/1.73 m2 and was classified using
the widely accepted KDIGO criteria.8 Thus, stage 1 CKD
was defined as kidney damage with a normal GFR
(>90 mL/min/1.73 m2). Stage 2 was defined as a mild
reduction in the GFR (60-89 mL/min/1.73 m2). Stage 3a
and 3b were defined as a moderate reduction in the
GFR (45-59 and 30-44 mL/min/1.73 m2, respectively).
Stage 4 CKD was defined as a severe reduction in the
GFR (15-29 mL/min/1.73 m2) and stage 5 as kidney failure
(GFR <15 mL/min/1.73 m2 or dialysis).
Statistical analysis. Categorical data are presented as
absolute numbers and percentages. Normally distributed
continuous variables are presented as the mean 6 stan-
dard deviation and non-normally distributed continuous
variables as the median and interquartile range (IQR). In-
dependent two-sample t-testswere used for the normally
distributed continuous variables. Spearman’s rho
nonparametric correlation test was used to evaluate the
possible correlation between the ischemia time and renal
function outcomes. Missing values were disregarded in
the variables if<2%of the valuesweremissing. TheP value
was considered statistically significant at P < .05. Statisti-
cal analysis was performed using SPSS, version 25.0, for
Windows (IBM Corp, Armonk, NY).
RESULTS
A total of 38 patients had undergone treatment from
2009 to 2019 at the 11 participating institutions for occlu-
sion of the renal bridging stent graft after F/B-EVAR. Their
mean age was 63.5 6 10 years, and 63.2% of the patients
were men. The median time between the aortic repair
and the diagnosis of renal occlusion was 7 months
(IQR, 0-14 months). The patient demographics and
comorbidities are presented in Table II. The underlying
aortic pathology previously treated with F/B-EVAR was
a degenerative aneurysm in 33 patients (86.8%), dissec-
tion in 4 (10.6%), and a mycotic aneurysm in 1 (2.6%). Of
the 38 patients, 16 (42.1%) had undergone FEVAR and
22 (57.9%) had undergone BEVAR. Six patients (15.8%)
had a solitary kidney. Eight patients (21.1%) had pre-
sented with bilateral renal graft occlusion; in all eight
cases, recanalization of both arteries was attempted.
The total number of target vessels (TVs) was 46, of which
21 (45.7%) had undergone FEVAR and 25 (54.3%), BEVAR.
Causes of renal stent graft occlusion. The cause of the
renal stent graft occlusion could not be identified for 23
of the 46 TVs (50%). However, for 19 (41.3%), a significant
Table II. Demographic characteristics (N ¼ 38 patients)
Characteristic Patients, No. (%)
Male sex 24 (63.2)
Coronary artery disease 12 (36.4)
Atrial fibrillation 2 (6.1)





Diabetes mellitus 2 (6.1)
Creatinine at admission, mg/dL
Median 3.1
Range 0.59-14.7
Stage 3 AKI (dialysis/predialysis) 17 (45)
Cerebrovascular disease 1 (3)
Peripheral arterial disease 7 (21.2)
Coagulopathy 8 (3.5)
Connective tissue disorder 3 (9.1)
Type of aortic pathology
Aneurysm 33 (86.8)
Dissection/postdissection aneurysm 4 (10.6)
Other 1 (2.6)
Type of endovascular aneurysm repair
Fenestrated EVAR 16 (42.1)
Branched EVAR 22 (57.9)
Only left renal stent graft occluded 13 (34.2)
Only right renal stent graft occluded 17 (44.7)
Bilateral occlusion 8 (21.1)
Solitary kidney 6 (15.8)
AKI, Acute kidney injury; EVAR, endovascular aortic repair.
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the causal factor. For the remaining cases, the causal
agent was presumed to be perioperative coagulopathy
(heparin-induced thrombopenia) in 2 TVs (4.3%), possible
mechanical destruction or embolism after relining of the
contralateral renal stent graft a few days earlier in 1 TV
(2.1%), and dehydration combined with planned
discontinuation of the antiplatelet therapy in 1 TV in a
patient receiving novel oral anticoagulant therapy (2.1%).
Operative characteristics. For endovascular recanaliza-
tion of the renal arteries, transfemoral access was used
for 10 patients (26.3%), transbrachial or transaxillary ac-
cess in 26 patients (68.4%), and both upper and lower ex-
tremity access in 2 patients (5.2%). The technical success
rate for the recanalization procedure was 95.7% (44 of
46 TVs). Catheterization of two TVs was unsuccessful.
The treatment strategy used was sole aspiration throm-
bectomy in 2 patients (5.3%), aspiration thrombectomyand relining of the renal stent grafts in 20 (52.6%), and
sole stent graft relining in 14 patients (36.8%). Selective
thrombolysis of the TV was used adjunctively in 20 of the
28 patients (52.6%). Of the 38 patients for whom aspira-
tion thrombectomy was used, manual thromboembolic
aspiration was used in 15 (39.5%), the Penumbra Indigo
thrombectomy device (Penumbra Inc, Alameda, Calif)
was implemented in 3 (7.9%), and the AngioJet throm-
bectomy system (Boston Scientific, Marlborough, Mass)
was used in 4 (10.5%). The mean procedure time was
140 6 66 minutes. The mean volume of contrast agent
used was 62 6 28 mL, and the mean fluoroscopy time
was 41.6 6 28 minutes. The perioperative and early
postoperative data are presented in Table III.
Early outcomes. Early mortality (first 30 days postoper-
atively) was 2.6%. One patient had died after cardiac ar-
rest of unknown cause on the 10th postoperative day.
Nomajor strokes occurred. Four patients (10.5%) had pre-
sented with access-related vascular complications, of
whom one (2.6%) had undergone surgical treatment of a
brachial artery occlusion immediately postoperatively.
Early renal function outcomes. On admission, 11 pa-
tients had presented with no renal function impairment
(29%) and 17 (44.7%) had presented with stage 3 AKI, ac-
cording to the KDIGO criteria. Ten patients (26.3%) had
presented with CKD stage 3 to 5 using the KDIGO criteria
for CKD. The estimated median renal ischemia time was
27.5 hours (range, 4-720 hours; IQR, 4-36 hours). Of the 38
patients, 94.4% had been treated after a minimum of
6 hours of renal ischemia time and 55.6% after 24 hours.
The 17 patients with stage 3 AKI had all required hemodi-
alysis perioperatively, at least intermittently. At 30 days,
10 of these patients (26.3%) required permanent hemodi-
alysis therapy. The clinical success of recanalization treat-
ment (ie, improvement of renal function) did not
correlate with the renal ischemia time (Spearman’s rho
correlation between estimated renal ischemia time and
DGFR, P ¼.354). Of the 14 patients with bilateral renal ar-
tery occlusion or a solitary kidney, nine had experienced
improvement in their renal function and no longer
required hemodialysis, although four had continued to
require hemodialysis. The course of the creatinine value
before, during, and after treatment is shown in Fig 1.
Late outcomes. The median follow-up time was
11 months (IQR, 0-28 months). Of the 38 patients, five
(13.2%) were lost to follow-up, none of whom had
required hemodialysis dependent at discharge. Of the
remaining 33 patients, 9 had required permanent he-
modialysis (23.7%) and 1 patient who had previously
required hemodialysis had undergone kidney trans-
plantation. Five patients had required procedural-related
reinterventions during follow-up (2.6% each). Of these
five patients, one had required renal stent graft relining
because of stenosis on the second postoperative month
Table III. Operative data and early (30-day) outcomesa
Variable
Patients (n ¼ 38) or target
vessels (n ¼ 46), No. (%)
Cause of occlusion
Unidentified 23/46 (50)
Stenosis/kinking of stent graft 19/46 (41.4)
Coagulopathy 2/46 (4.3)
Other 2/46 (4.3)






Only aspiration thrombectomy 2 (5.3)
Aspiration thrombectomy and
relining of bridging stent
graft
20 (52.6)
Only relining 14 (36.8)
Type of thrombectomy







Technical success 44/46 (95.7)
Death 1 (2.6)
Access vessel complication 4 (10.5)
Type of bridging stent graft used













aThe cause of occlusion, technical success, and type of bridging stent
graft used refer to the target vessels with a denominator of 46; the
remaining values refer to the patient cohort (n ¼ 38).
bGetinge AB, Gothenburg, Sweden.
cW.L. Gore and Associates, Inc, Flagstaff, Ariz.
dBard Peripheral Vascular Inc, Tempe, Ariz.
eBentley InnoMed GmbH, Hechingen, Germany.
f Medtronic, Dublin, Ireland.
gCardinal Health, Dublin, Ireland.
hCook Medical, Bloomington, Ind.
Fig 1. Course of creatinine value before, during, and after
treatment.
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May 2021(POM). One had undergone attempted recanalization of
a distal renal artery stent graft for restenosis on the sec-
ond POM. However, the procedure was aborted because
of an intraprocedural transient ischemic attack. One
patient had required recanalization of the renal stent
graft because of new occlusion in the third POM. One
patient had required drug-coated balloon angioplasty to
treat distal renal stent graft stenosis in the 24th POM.
Finally, one patient had undergone relining of the renal
stent graft for stenosis in the 57th POM. No reduction in
the GFR value was observed in the patient with reoc-
clusion. The Kaplan-Meier survival analysis and estima-
tion of reintervention and patency after recanalization
are presented in Figs 2 and 3.
DISCUSSION
Abdominal aortic aneurysms, including juxtarenal, par-
arenal, and thoracoabdominal aneurysms, have been
increasingly treated by endovascular repair, mainly
owing to its lower short- and midterm morbidity and
mortality rates.9-11 Of the different available endovascular
options, F/B-EVAR procedures have the largest body of
evidence and have been recommended by the guide-
lines.11,12 Other endovascular solutions, such as chimneys,
periscopes, and snorkels, should be limited to emer-
gency settings or when F/B-EVAR cannot be used
because of anatomic limitations or availability.
Visceral vessel patency is one of the most important
mid- and long-term aspects after F/B-EVAR. A recent
analysis of 354 patients and a total of 1305 target reno-
visceral vessels reported primary patency rates for the
left and right renal arteries of 94% and 92% at 36 months,
respectively.3 Another recent analysis of 523 target reno-
visceral vessels found an overall visceral vessel loss of
3.8% at 38 months of follow-up, with a greater incidence
Fig 2. Kaplan-Meier survival estimation curve, with all re-
sults represented within a standard error of 10%.
Fig 3. Kaplan-Meier freedom from reintervention estima-
tion curve, with all results represented within a standard
error of 10%.
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Volume 73, Number 5(6.4%) after treatment of thoracoabdominal aneurysms
and after BEVAR (compared with FEVAR; 9% vs 2%).
They found an overall visceral vessel loss of 4.4% of
renal arteries, with 13% after BEVAR compared with
2.5% after FEVAR (P ¼ .001).13 Another recent study
specifically of RAO found an incidence of 3.3% at
11 months of follow-up.14 However, although the inci-
dence and magnitude of the complication has been
reported with greater frequency, available, high-
quality data regarding the possible treatment options
and outcomes are lacking.
At present, only a few case reports and one case series
have been reported. Heidemann et al14 performed a
single-center retrospective analysis of seven patients
(nine cases of RAO) who had undergone successful treat-
ment by endovascular recanalization from December
2014 to March 2017. They found that renal function can
be salvaged, even if the revascularization procedure has
been delayed.14 They reported a 100% secondary patency
rate found on follow-up CTA, without any cases of per-
manent dialysis postoperatively.14 The mean renal
ischemic time to revascularization was 24 hours (range,
7-168 hours). In contrast, in the present study, the median
renal ischemia time was 27.5 hours (range, 4-720 hours),
slightly longer than that reported by Heidemann et al,14
with a larger range of values. This might reflect different
patterns of patient referral from the primary and second-
ary institutions to tertiary hospitals with a vascular team
associated with each specific country. The findings
from the present study second the idea that regardless
of whether revascularization has been performed after
>6 hours of renal ischemia, renal function and urineoutput can potentially be salvaged. However, the clinical
success did not correlate with the renal ischemia time,
possibly owing to the small sample size and the exis-
tence of extreme outliers. Although after revasculariza-
tion, 10 patients were discharged requiring permanent
hemodialysis (26.3%), 17 (44.7%) had required temporary
hemodialysis at admission, a reduction in the hemodial-
ysis rate of nearly 20%. Even patients who will continue
to require dialysis might benefit from recanalization if
relevant urine output can be preserved that will allow
for better fluid management.
Regarding the technique of reestablishing flow to the
renal artery, no concrete suggestions can be provided
from our findings, given the heterogeneity of the ap-
proaches used, which ranged from simple aspiration
thrombectomy to sole stenting of the recanalized renal
branch and artery. In the latter, it was presumed that
the thrombus had been pushed between the previous
and new stent grafts.
An essential topic is the timing of attempting revascu-
larization. Increasing experience has demonstrated that
determining which patients will have a good chance of
having their renal function significantly improved is not
predictable. The length of occlusion time should not be
the only parameter used to determine whether to rein-
tervene. Even after prolonged occlusion of weeks, the
collateral vascular network can maintain the viability of
the renal parenchyma and lead to complete renal func-
tion restoration once antegrade perfusion to the kidney
has been established. Although revascularization within
24 hours should always be pursued, a good indicator of
whether to proceed with late revascularization could
1572 Konstantinou et al Journal of Vascular Surgery
May 2021be the presence of renal parenchyma perfusion on color
Doppler or contrast-enhanced renal ultrasound scan or
in the venous phase of a CTA scan.
Finally, the results from the present study have under-
lined the significance of adequately informing all pa-
tients undergoing F/B-EVAR and their primary care
physicians regarding the possible event of renal stent
graft occlusion, because timely intervention can possibly
prevent the patient from requiring dialysis. This informa-
tion could prove essential in preventing unnecessary de-
lays in the diagnosis and treatment of renal stent graft
occlusion, because most primary care physicians will
not be familiar with complex aortic repair and its
possible complications and might, therefore, not suspect
it. Moreover, a high degree of suspicion is required for a
timely diagnosis because renal artery occlusions can pre-
sent with nonspecific symptoms, including flank pain,
nausea or vomiting, and diarrhea.2
Study limitations. The present study was designed as a
retrospective registry of recanalized renal arteries with a
focus on the feasibility and effect of the treatment. The
incidence of RAO after F/B-EVAR procedures cannot be
calculated from the data available in the present study,
given that the centers were asked only to include all cases
in which RAO had been diagnosed and treated. Thus, the
total number of FEVAR procedures performed in each
center for the study period was unknown. Overall, the
renal stent occlusion rates per center, incidence of occlu-
sion of different stent types, and technical details con-
cerning the initial F-BEVAR were beyond the scope of the
present study. Furthermore, only patients who had
received treatmentwere included; thus, the present study
lacked a “control” group in which RAO was detected but
left untreated (patients without any contrast in the kidney
parenchyma found on the preoperative CTA or duplex
ultrasound scan). Moreover, because the clinical presen-
tation of AKI can vary, the estimation of the renal ischemic
time was an “as-close-as-possible” approximation to the
real value, although the risk of over- or underestimation
could not be completely avoided.
Thus, the present study included data from a cohort of
patients, which, although retrospective and multicenter
in nature (different treatment strategies and protocols,
different medications and stent grafts), had good
external validity and represents an accurate “real-world”
experience.
CONCLUSIONS
Revascularization of occluded renal bridging stent
grafts after F/B-EVAR is a safe and feasible technique,
which can lead to significant improvement of renal func-
tion, even after long ischemia times (>24 hours) of the
renal parenchyma or bilateral occlusion. Also, the long-
term patency rates justify aggressive management of
renal artery occlusion after F/B-EVAR.AUTHOR CONTRIBUTIONS
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